About This Deal

AbbVie acquired Aliada Therapeutics Holdings, Inc. for $1.4 billion upfront, a transaction completed in December 2024, structured as all cash (asset acquisition).

Aliada Therapeutics Holdings, Inc. operates in Neuroscience (CNS). Aliada is advancing therapies using a novel blood-brain-barrier-crossing technology to address central nervous system diseases. Its lead asset, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Abeta) antibody in development for Alzheimer's disease. AbbVie paid approximately $1.4 billion upfront and accounted for the transaction as an asset acquisition.

Adds a differentiated blood-brain-barrier platform and an Alzheimer's asset to AbbVie's neuroscience pipeline.

Deal Terms

Acquirer
AbbVie
Target
Aliada Therapeutics Holdings, Inc.
Value
$1.4 billion upfront
Date
December 2024
Type
Full acquisition
Status
Ready

Transaction Details

Segment
Neuroscience (CNS)
Structure
All cash (asset acquisition)
Announced
October 1, 2024
Closed
December 1, 2024

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.